Trials / Completed
CompletedNCT00239486
Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)
Evaluation of the Effect of Different Doses of Pramipexole on Subjective and Objective Symptoms of Idiopathic Restless Legs Syndrome (RLS).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 109 (planned)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the efficacy and safety of different doses of pramipexole (Sifrol) on subjective and objective symptoms of idiopathic Restless Legs Syndrome (RLS) and also to determine the optimal dose of pramipexole in patients with RLS by polysomnography and evaluation of clinical improvement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pramipexole |
Timeline
- Start date
- 2002-10-01
- Primary completion
- 2004-04-01
- Completion
- 2004-04-01
- First posted
- 2005-10-17
- Last updated
- 2013-11-01
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT00239486. Inclusion in this directory is not an endorsement.